Related Experiment Video
Updated: Mar 16, 2026

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
Published on: January 26, 2024
Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis
Mitsuyo Yoshida1, Ayumi Taguchi1, Kei Kawana1
1Department of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan.
Abstract:
The most common properties of oncogenes are cell proliferation and the prevention of apoptosis in malignant cells, which, as a consequence, induce tumor formation and dissemination. However, the effects of oncogenes on the tumor microenvironment (TME) have not yet been examined in detail. The accumulation of ascites accompanied by chronic inflammation and elevated concentrations of VEGF is a hallmark of the progression of ovarian cancer. We herein demonstrated the mechanisms by which oncogenes contribute to modulating the ovarian cancer microenvironment. c-MYC and KRAS were transduced into the mouse ovarian cancer cell line ID8. ID8, ID8-c-MYC, or ID8-KRAS cells were then injected into the peritoneal cavities of C57/BL6 mice and the production of ascites was assessed. ID8-c-MYC and ID8-KRAS both markedly accelerated ovarian cancer progression in vivo, whereas no significant differences were observed in proliferative activity in vitro. ID8-KRAS in particular induced the production of ascites, which accumulated between approximately two to three weeks after the injection, more rapidly than ID8 and ID8-c-MYC (between nine and ten weeks and between six and seven weeks, respectively). VEGF concentrations in ascites significantly increased in c-MYC-induced ovarian cancer, whereas the concentrations of inflammatory cytokines in ascites were significantly high in KRAS-induced ovarian cancer and were accompanied by an increased number of neutrophils in ascites. A cytokine array revealed that KRAS markedly induced the expression of granulocyte macrophage colony-stimulating factor (GM-CSF) in ID8 cells. These results suggest that oncogenes promote cancer progression by modulating the TME in favor of cancer progression.
Insights
Oncogenes like c-MYC and KRAS accelerate ovarian cancer progression by altering the tumor microenvironment (TME). KRAS promotes ascites and inflammation, while c-MYC increases VEGF, impacting tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Oncogenes typically drive cell proliferation and inhibit apoptosis, leading to tumor formation.
- The impact of oncogenes on the tumor microenvironment (TME) is not fully understood.
- Ovarian cancer progression involves ascites, inflammation, and elevated VEGF.
Purpose of the Study:
- To investigate how oncogenes (c-MYC, KRAS) modulate the ovarian cancer TME.
- To determine the in vivo effects of oncogene transduction on ovarian cancer progression and ascites formation.
- To analyze changes in VEGF and inflammatory markers within the TME.
Main Methods:
- Transduction of c-MYC and KRAS into the ID8 mouse ovarian cancer cell line.
- Injection of modified ID8 cells into C57/BL6 mice to assess tumor progression and ascites production.
- Measurement of VEGF and inflammatory cytokines in ascites; cytokine array analysis.
Main Results:
- Both ID8-c-MYC and ID8-KRAS accelerated ovarian cancer progression in vivo, with no significant difference in vitro proliferation.
- ID8-KRAS induced rapid ascites accumulation (2-3 weeks) compared to ID8-c-MYC (6-7 weeks) and ID8 (9-10 weeks).
- c-MYC elevated VEGF in ascites; KRAS increased inflammatory cytokines and neutrophils, notably granulocyte macrophage colony-stimulating factor (GM-CSF).
Conclusions:
- Oncogenes promote ovarian cancer progression by actively reshaping the tumor microenvironment.
- KRAS and c-MYC utilize distinct TME-modulating mechanisms, influencing ascites, inflammation, and VEGF levels.
- Targeting oncogene-driven TME alterations could offer new therapeutic strategies for ovarian cancer.

